|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUDCD1 |
Gene summary for NUDCD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUDCD1 | Gene ID | 84955 |
| Gene name | NudC domain containing 1 | |
| Gene Alias | CML66 | |
| Cytomap | 8q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q96RS6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84955 | NUDCD1 | SYSMH3 | Human | Oral cavity | OSCC | 4.14e-21 | 5.03e-01 | 0.2442 |
| 84955 | NUDCD1 | SYSMH5 | Human | Oral cavity | OSCC | 6.57e-03 | 1.08e-01 | 0.0647 |
| 84955 | NUDCD1 | P1_cSCC | Human | Skin | cSCC | 7.16e-04 | 3.08e-01 | 0.0292 |
| 84955 | NUDCD1 | P2_cSCC | Human | Skin | cSCC | 2.69e-03 | 2.29e-01 | -0.024 |
| 84955 | NUDCD1 | P4_cSCC | Human | Skin | cSCC | 4.66e-03 | 3.20e-01 | -0.00290000000000005 |
| 84955 | NUDCD1 | P10_cSCC | Human | Skin | cSCC | 7.40e-17 | 5.67e-01 | 0.1017 |
| 84955 | NUDCD1 | male-WTA | Human | Thyroid | PTC | 4.82e-06 | 4.90e-02 | 0.1037 |
| 84955 | NUDCD1 | PTC01 | Human | Thyroid | PTC | 7.68e-09 | 3.96e-02 | 0.1899 |
| 84955 | NUDCD1 | PTC05 | Human | Thyroid | PTC | 5.38e-04 | 1.45e-01 | 0.2065 |
| 84955 | NUDCD1 | PTC06 | Human | Thyroid | PTC | 6.23e-06 | 1.39e-01 | 0.2057 |
| 84955 | NUDCD1 | PTC07 | Human | Thyroid | PTC | 1.74e-24 | 1.45e-01 | 0.2044 |
| 84955 | NUDCD1 | ATC09 | Human | Thyroid | ATC | 1.94e-06 | 1.92e-01 | 0.2871 |
| 84955 | NUDCD1 | ATC12 | Human | Thyroid | ATC | 7.18e-13 | 1.18e-01 | 0.34 |
| 84955 | NUDCD1 | ATC13 | Human | Thyroid | ATC | 3.85e-17 | 3.19e-01 | 0.34 |
| 84955 | NUDCD1 | ATC1 | Human | Thyroid | ATC | 5.52e-05 | 2.17e-01 | 0.2878 |
| 84955 | NUDCD1 | ATC2 | Human | Thyroid | ATC | 8.94e-10 | 8.65e-01 | 0.34 |
| 84955 | NUDCD1 | ATC4 | Human | Thyroid | ATC | 3.74e-09 | 1.90e-01 | 0.34 |
| 84955 | NUDCD1 | ATC5 | Human | Thyroid | ATC | 1.55e-23 | 3.65e-01 | 0.34 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUDCD1 | SNV | Missense_Mutation | c.1152N>C | p.Met384Ile | p.M384I | Q96RS6 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| NUDCD1 | SNV | Missense_Mutation | rs543121980 | c.850N>A | p.Glu284Lys | p.E284K | Q96RS6 | protein_coding | tolerated(0.49) | benign(0.346) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDCD1 | SNV | Missense_Mutation | c.1554N>A | p.Phe518Leu | p.F518L | Q96RS6 | protein_coding | deleterious(0.01) | possibly_damaging(0.76) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NUDCD1 | SNV | Missense_Mutation | c.1643N>G | p.Ala548Gly | p.A548G | Q96RS6 | protein_coding | deleterious(0.01) | benign(0.133) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| NUDCD1 | SNV | Missense_Mutation | c.571N>A | p.Glu191Lys | p.E191K | Q96RS6 | protein_coding | deleterious(0.03) | benign(0.217) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| NUDCD1 | deletion | Frame_Shift_Del | novel | c.1457delT | p.Leu486Ter | p.L486* | Q96RS6 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| NUDCD1 | SNV | Missense_Mutation | c.488N>A | p.Pro163His | p.P163H | Q96RS6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| NUDCD1 | SNV | Missense_Mutation | novel | c.589N>C | p.Ser197Arg | p.S197R | Q96RS6 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDCD1 | SNV | Missense_Mutation | novel | c.544N>G | p.Thr182Ala | p.T182A | Q96RS6 | protein_coding | tolerated(0.11) | benign(0) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| NUDCD1 | SNV | Missense_Mutation | novel | c.1746N>T | p.Glu582Asp | p.E582D | Q96RS6 | protein_coding | tolerated(0.48) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |